BioSpace News Archive

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of targeted oncolytic immunotherapeutics for cancer based on Seneca Valley Virus, announced the successful development of a novel SVV-001 Patient Screening Test.

NanoViricides, Inc., a global leader in nanomedicines against viruses, announced that it has completed the process of licensing the human Coronavirus field for drug development and commercialization from TheraCour Pharma, Inc.

Vanqua Bio, a Chicago-based biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, announced that it closed an $85 million Series B financing round, led by Omega Funds.

Zimmer Biomet Holdings, Inc., a global medical technology leader, announced key appointments to the “NewCo” leadership team, including Richard J. Heppenstall as Executive Vice President and Chief Financial Officer.

DermTech Study, “Non-Invasive Detection of Genomic Atypia Increases Real-World NPV and PPV of the Melanoma Diagnostic Pathway and Reduces Biopsy Burden,” Published in SKIN: The Journal Of Cutaneous Medicine

Rocket Pharmaceuticals, Inc. today announces an oral presentation of previously disclosed data from the ongoing Phase 1 trial of RP-A501 for the treatment of Danon Disease was given at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2021.

Three Finnish biotech companies - Abacus Diagnostica, Kaivogen and Labrox - are joining forces to form an international frontrunner in in vitro diagnostics.

Progenity, Inc. announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,112,403 for assessment of preeclampsia using assays for free and dissociated placental growth factor.

Accuray Incorporated (NASDAQ: ARAY) announced today that data from the PACE – Prostate Advances in Comparative Evidence – trial indicate the company’s CyberKnife® robotic radiotherapy platform is superior to conventional linear accelerators in reducing the incidence of late grade two or higher bladder toxicity associated with prostate cancer stereotactic body radiation therapy (SBRT) treatments.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline.